- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04923282
Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects
A Double Blind, Randomized, Single Center, Single and Multiple Dose, Pharmacokinetic, Safety and Tolerability Study of Recombinant Human Alkaline Phosphatase (recAP) Administered Intravenously in Healthy Japanese Subjects
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This study is a randomized, double blind, parallel group, single-center trial, consisting of a single dose part and a multiple dose part in 32 healthy Japanese subjects. Since all these doses have been studied before and safety extensively evaluated in non-Japanese subjects and no ethnic sensitivity is expected, the groups can be dosed in parallel.
Part A will have 3 parallel groups of 8 male subjects with N=6 on active and N=2 on placebo per group. Following baseline assessments, a single dose of recAP will be administered by a one-hour infusion followed by samplings for pharmacokinetic evaluation and routine safety assessments.
Part B will have a single group of 8 male subjects with N=6 on active and N=2 on placebo. Following baseline assessments, recAP will be dosed on Days 1, 2 and 3 by one-hour infusions followed by samplings for pharmacokinetic evaluation and routine safety assessments.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Tokyo, Japan, 192-0071
- P-one clinic, Keikokai medical corporation
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Gender : male
- Age : 20-55 years, inclusive
- Body mass index (BMI) : 18.0-30.0 kg/m2, inclusive
- Subjects must be Japanese by birth, have resided outside Japan <10 years, have parents and maternal and paternal grandparents who are Japanese, and primarily consume a Japanese diet.
- Resting supine blood pressure at screening showing no clinically relevant deviations from normal as judged by the Principal Investigator.
- Computerized (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations.
- All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Investigator.
- Ability and willingness to abstain from alcohol and tobacco products from 48 h prior to entry in the clinical research center until discharge.
- Easily accessible veins for venipuncture and catheter placing.
- Willingness to sign the written informed consent form (ICF).
- Subjects must agree to use adequate contraception when sexually active. This applies for the time period between end of first administration and 14 days after the last administration of study drug.
Exclusion Criteria:
- Evidence of clinically relevant pathology.
- History of relevant drug and/or food allergies.
- Subject has a history of clinically significant abnormalities or of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- Use of medication, except for acetaminophen (paracetamol), which is allowed up to 3 days before entry into the clinical research center (after that time the use of a limited amount of acetaminophen is permitted after consultation with the Principal Investigator).
- Subject is mentally or legally incapacitated, has significant emotional problems at the time of screening visit or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder over the last year.
- Participation in a drug study within 60 days prior to drug administration.
- Donation of more than 500 mL of blood within 60 days prior to drug administration. Donation of more than 1.5 liters of blood (for men) in the 10 months preceding the start of this study
- Smoking more than 5 cigarettes, 1 cigar or 1 pipe daily.
- History of alcohol abuse or drug addiction (including soft drugs like cannabis products).
- Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants) and/or alcohol breath test at Screening and/or Pre-Dose.
- Intake of more than 14 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine/Japanese Sake or 35 mL of spirits).
- Positive screen on hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV) or anti-human immunodeficiency virus (anti-HIV)-1 or anti-HIV-2 or HIV-1/2 antigen.
- Illness within 5 days prior to (the first) drug administration.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo
single 1-hour IV infusion of 0.8 mg/kg recAP or placebo
|
Intravenous infusion
Intravenous infusion
|
Aktiver Komparator: Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo
single 1-hour IV infusion of 1.6 mg/kg recAP or placebo
|
Intravenous infusion
Intravenous infusion
|
Aktiver Komparator: Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo
single 1-hour IV infusion of 3.2 mg/kg recAP or placebo
|
Intravenous infusion
Intravenous infusion
|
Aktiver Komparator: Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3
1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3
|
Intravenous infusion
Intravenous infusion
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Maximum observed recAP plasma concentration (Cmax) after single dose
Zeitfenster: Single dose 9 days treatment phase
|
Blood collection for cmax evaluation daily from Day 1 to Day 9
|
Single dose 9 days treatment phase
|
Time to attain maximum recAP serum concentration (Tmax) after single dose
Zeitfenster: Single dose 9 days treatment phase
|
Blood collection for Tmax evaluation daily from Day 1 to Day 9
|
Single dose 9 days treatment phase
|
Area under the plasma concentration versus time curve (AUC) after single dose
Zeitfenster: Single dose 9 days treatment phase
|
Blood collection for AUC evaluation daily from Day 1 to Day 9
|
Single dose 9 days treatment phase
|
recAP elimination half-life ( t1/2) after single dose
Zeitfenster: Single dose 9 days treatment phase
|
Blood collection for t1/2 evaluation daily from Day 1 to Day 9
|
Single dose 9 days treatment phase
|
Maximum observed recAP plasma concentration (Cmax) after multiple doses
Zeitfenster: Multiple doses 13 days treatment phase
|
Blood collection for cmax evaluation daily from Day 1 to Day 13
|
Multiple doses 13 days treatment phase
|
Time to attain maximum recAP serum concentration (Tmax) after multiple doses
Zeitfenster: Multiple doses 13 days treatment phase
|
Blood collection for Tmax evaluation daily from Day 1 to Day 13
|
Multiple doses 13 days treatment phase
|
Area under the plasma concentration versus time curve (AUC) after multiple doses
Zeitfenster: Multiple doses 13 days treatment phase
|
Blood collection for AUC evaluation daily from Day 1 to Day 13
|
Multiple doses 13 days treatment phase
|
recAP elimination half-life ( t1/2) after multiple doses
Zeitfenster: Multiple doses 13 days treatment phase
|
Blood collection for t1/2 evaluation daily from Day 1 to Day 13
|
Multiple doses 13 days treatment phase
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Adverse events (AEs) after single dose
Zeitfenster: Single dose 9 days treatment phase
|
Any untoward medical occurrence in a subject enrolled into a clinical study regardless of its causal relationship to study drug.
|
Single dose 9 days treatment phase
|
Adverse events (AEs) after multiple doses
Zeitfenster: Multiple doses 13 days treatment phase
|
Any untoward medical occurrence in a subject enrolled into a clinical study regardless of its causal relationship to study drug.
|
Multiple doses 13 days treatment phase
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Annelies Legters, AM-Pharma
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- AP-recAP-AKI-01-02
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur single 1-hour IV infusion of 0.8 mg/kg recAP
-
SOS Attaque CérébraleBeendetInfarkt, Arteria cerebri mediaFrankreich
-
Center for International Blood and Marrow Transplant...National Marrow Donor ProgramAbgeschlossenHLA-Mismatched Nonrelated Donor Bone Mark Transplantation with Post-Transplantation CyclophosphamideChronische lymphatische Leukämie (CLL) | Myelodysplastisches Syndrom (MDS) | Akute myeloische Leukämie (AML) | Chemotherapie-sensitives Lymphom | Akute lymphoblastische Leukämie (ALL)/T-lymphoblastisches Lymphom | Akute biphänotypische Leukämie (ABL) | Akute undifferenzierte Leukämie (AUL)Vereinigte Staaten
-
Centre for Human Drug Research, NetherlandsMaruho Co., Ltd.Abgeschlossen